Summary
The provided prompt does not include actual AI-generated prescribing-information claims to verify; only non-label statements about FDA approval year and general approval-date differences are present, which are unsupported by the supplied labeling excerpts.
Category Scores
Accurate Statements
Unsupported Statements
Vraylar (cariprazine) received FDA approval in 2015.
The supplied prescribing information excerpts do not state or support the drug’s FDA approval year.
The FDA-approval-based release year for Vraylar is generally cited as 2015 in the US market.
The supplied prescribing information excerpts provide no information about market release year or commonly cited approval/release timing.
Later expansions (new indications) can have different FDA approval dates in the US or approval dates in other countries for Vraylar.
The supplied prescribing information excerpts do not address approval dates for new indications or cross-country approval date differences.
Contradictions
Important Omissions
No evaluation can be performed against label-supported prescribing content (e.g., boxed warnings, contraindications, dosing/administration, approved indications) because the provided statements are not from those sections and no specific label-mapped claim text is given.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements evaluated concern FDA approval timing, not dosing/safety/contraindications; however, they are unsupported by the provided labeling excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about FDA approval/release year and general approval-date differences are not supported by the supplied FDA prescribing information excerpts.
Suggested Improvement
Limit claims to information explicitly present in the provided prescribing information (e.g., boxed warnings, contraindications, approved indications, dosing/administration). If approval year is needed, provide label text or an FDA approval source that is included in the materials being evaluated.